Liquid Biopsy Advances And Medicare Decisions Will Reshape Precision Medicine

Shared on01 May 25
Fair value Decreased 4.69%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 5.86%

AnalystConsensusTarget has increased future PE multiple from 45.9x to 51.0x and decreased shares outstanding growth rate from 0.3% to 0.1%.